Business
RO LAUNCHES ELI LILLY'S KWIKPEN®, OFFERING PATIENTS A MORE CONVENIENT WAY TO TAKE ZEPBOUND®
Ro, the leading direct-to-patient healthcare company, today announced that it is working with Eli Lilly to launch the recently FDA-approved Zepbound® (tirzepatide) KwikPen® nationwide on its platform. The prefilled, multi-dose pen offers a convenient way for patients to take the most effective GLP-1 medication available. Patients can visit Ro.co to access the KwikPen along with ongoing high-quality clinical care, including 24/7 messaging, 1-1 coaching, educational content, weight tracking and do
About this update from Eli Lilly And Company
[{"type":"text","content":"The most effective GLP-1 medication is now available in a multi-dose pen","length":72,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, April 2, 2026 /PRNewswire/ -- Ro, the leading direct-to-patient healthcare company, today announced that it is working with Eli Lilly to launch the recently FDA-approved Zepbound® (tirzepatide) KwikPen® nationwide on its platform. The prefilled, multi-dose pen offers a convenient way for patients to take the most effective GLP-1 medication available. Patients can visit Ro.co to access the KwikPen along with ongoing high-quality clinical care, including 24/7 messaging, 1-1 coaching, educational content, weight tracking and dose logging, side-effect monitoring, and more.","length":585,"tagName":"p"},{"type":"image","alt":"Zepbound KwikPen now on Ro","displaySize":"","headline":null,"caption":"Zepbound KwikPen now on Ro","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":225,"url":"https://media.zenfs.com/en/prnewswire.com/603792dd17644afff089446371235f76"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FLnUsB4oMh2r.QeETGHteg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM5Nw--/https://media.zenfs.com/en/prnewswire.com/603792dd17644afff089446371235f76","width":400,"height":225}},"href":"https://mma.prnewswire.com/media/2949178/Ro_Zepbound_KwikPen.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""By working with Eli Lilly to make the KwikPen accessible on Ro's platform, we're continuing to help patients access the latest treatments, in the most innovative form factors, at the lowest possible cost," said Zach Reitano, co-founder and CEO of Ro.","length":269,"tagName":"p"},{"type":"text","content":"Ro connected its platform with Eli Lilly's direct-to-patient offering in December 2024 to expand access to FDA-approved, authentic Zepbound. Ro has since played a key role in bringing new Zepbound treatment delivery options to market faster while ensuring patients can access them at the lowest available cash pay price.","length":324,"tagName":"p"},{"type":"text","content":"The Zepbound KwikPen is available to cash-pay patients with upfront, transparent pricing. Monthly pricing starts at $299 for the 2.5 mg starter dose and $399 for the 5 mg dose. For higher doses (7.5 mg, 10 mg, 12.5 mg, and 15 mg), eligible patients can ac...